- Home
- CLYM vs SLS Comparison
CLYM vs SLS Comparison
Compare CLYM & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLYM
- SLS
- Stock Information
- Founded
- CLYM 2018
- SLS 2012
- Country
- CLYM United States
- SLS United States
- Employees
- CLYM N/A
- SLS N/A
- Industry
- CLYM
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- CLYM
- SLS Health Care
- Exchange
- CLYM NYSE
- SLS Nasdaq
- Market Cap
- CLYM 83.1M
- SLS 89.6M
- IPO Year
- CLYM 2021
- SLS N/A
- Fundamental
- Price
- CLYM $1.19
- SLS $1.56
- Analyst Decision
- CLYM
- SLS
- Analyst Count
- CLYM 0
- SLS 0
- Target Price
- CLYM N/A
- SLS N/A
- AVG Volume (30 Days)
- CLYM 125.8K
- SLS 2.0M
- Earning Date
- CLYM 05-19-2025
- SLS 05-20-2025
- Dividend Yield
- CLYM N/A
- SLS N/A
- EPS Growth
- CLYM N/A
- SLS N/A
- EPS
- CLYM N/A
- SLS N/A
- Revenue
- CLYM N/A
- SLS N/A
- Revenue This Year
- CLYM N/A
- SLS N/A
- Revenue Next Year
- CLYM N/A
- SLS N/A
- P/E Ratio
- CLYM N/A
- SLS N/A
- Revenue Growth
- CLYM N/A
- SLS N/A
- 52 Week Low
- CLYM $1.05
- SLS $0.77
- 52 Week High
- CLYM $10.23
- SLS $1.85
- Technical
- Relative Strength Index (RSI)
- CLYM N/A
- SLS 61.26
- Support Level
- CLYM N/A
- SLS $1.60
- Resistance Level
- CLYM N/A
- SLS $1.85
- Average True Range (ATR)
- CLYM 0.00
- SLS 0.13
- MACD
- CLYM 0.00
- SLS 0.02
- Stochastic Oscillator
- CLYM 0.00
- SLS 50.85
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.